Physician profile
John A Abikhaled
NPI 1639108731
$18,842.85
in general payments reported to CMS, 2019-2025
32 companies · $233 in 2025
The $233 reported for 2025 was less than what a typical Surgery provider received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $8,538 · 2020: $7,410 · 2021: $708 · 2022: $773 · 2023: $578 · 2024: $603 · 2025: $233.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,414.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,414.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $15,826.30 | 2019-2023 | Da Vinci Surgical System |
| Davol INC. | $634.00 | 2019-2024 | Arista Ah Flexitip, Phasix Mesh |
| Medtronic, INC. | $368.50 | 2021-2024 | Endoflip |
| Ethicon US, LLC | $311.14 | 2019-2022 | |
| Kerecis Limited | $255.44 | 2021-2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide, Kerecis Omega3 Marigen |
| Boston Scientific Corporation | $171.74 | 2024-2025 | Axios, Spyglass Discover |
| Endogastric Solutions, INC | $164.26 | 2023 | Esophyx |
| W. L. Gore & Associates, INC. | $133.65 | 2022-2024 | Gore Enform Preperitoneal Biomaterial |
| Covidien LP | $122.86 | 2019 | |
| Allergan, INC. | $118.23 | 2021 | |
| Becton, Dickinson and Company | $85.49 | 2024 | Arista Ah Flexitip |
| Takeda Pharmaceuticals U.S.A., INC. | $65.79 | 2021-2024 | Gattex |
| Lexington Medical, INC. | $65.07 | 2025 | Aeon Endostapler & Echelon Flex Powered Stapler |
| Smith+Nephew, INC. | $63.48 | 2021-2024 | Stravix Pl |
| Integra Lifesciences Corporation | $59.99 | 2023-2025 | Integra, Integra Dermal Regeneration Template, Primatrix |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hologic Sales and Service, LLC | $50.72 | 2022 | |
| Heron Therapeutics, INC. | $41.16 | 2021 | |
| Tetraphase Pharmaceuticals, INC. | $37.51 | 2020 | |
| Mimedx Group, INC. | $35.07 | 2024 | |
| Conmed Corporation | $33.33 | 2019 | |
| Senseonics, Incorporated | $32.00 | 2019-2020 | |
| Innocoll Pharmaceuticals Limited | $22.60 | 2022 | |
| Merit Medical Systems INC | $21.83 | 2020 | |
| Abbott Laboratories | $19.26 | 2024 | Proclaim |
| Mallinckrodt Enterprises LLC | $18.63 | 2019 | |
| Shire North American Group INC | $18.51 | 2019 | |
| Baxter Healthcare | $16.76 | 2021 | |
| Karl Storz Endoscopy-America | $16.55 | 2024 | N.A. |
| Cook Medical LLC | $12.22 | 2019 | |
| Lsi Solutions INC | $12.00 | 2022 | |
| Bolder Surgical LLC | $8.76 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$601,293.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Abikhaled listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.